| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H16N2O |
| Molecular Weight | 288.3431 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(CC1=CC=C(C=C1)C2=CC=CC=C2)NC3=CC=CC=N3
InChI
InChIKey=PWHROYKAGRUWDQ-UHFFFAOYSA-N
InChI=1S/C19H16N2O/c22-19(21-18-8-4-5-13-20-18)14-15-9-11-17(12-10-15)16-6-2-1-3-7-16/h1-13H,14H2,(H,20,21,22)
| Molecular Formula | C19H16N2O |
| Molecular Weight | 288.3431 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Diphenpyramide is a non-steroidal anti-inflammatory compound, that has been studied in degenerative and inflammatory arthropathies treatment. In animal tests, Diphenpyramide showed anti-inflammatory action as powerful as that of indomethacin or phenylbutazone, with major peripheral analgesic, antipyretic and uricosuric properties. The therapeutic index was more favorable than that of the reference compounds. Diphenpyramide inhibits the synthesis of inflammatory prostaglandins and antagonizes the mediators of inflammation, but does not affect platelet aggregation or blood clotting. The anti-inflammatory action of diphenpyramide has been extensively proven in clinical trials in which patients with various inflammatory conditions, mainly of a musculoskeletal nature, were treated. The overall therapeutic efficacy was over 80% with a high proportion of osteoarthritis. In double-blind studies, the efficacy of Diphenpyramide was significantly better than that of acetylsalicylic acid or indomethacin in osteoarthritis and comparable with that of naproxen. Side-effects were seldom reported, were mild and transient and mainly of a gastrointestinal nature.
